NATAN DAVID 4

What Happened

• Natan David, a director of Sunshine Biopharma, received a grant/stock award of 100,000 shares on 2026-04-14. The reported acquisition price is $0.00, so the filing shows $0 cash paid for the award. This is an award (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-14; Transaction type/code: Award (A).
• Shares granted: 100,000; Reported price per share: $0.00; Reported cash value: $0.
• Footnote: F1 — represents a stock award to the reporting person.
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Report filed the same day (timely).

Context

• Stock awards to directors are typically compensation and may be subject to vesting or other restrictions; the filing does not disclose vesting or sale activity. Such awards are routine director compensation and do not by themselves indicate buying or selling sentiment.